Bildkälla: Stockfoto

Idogen: Rights issue outcome announced - Redeye

Redeye leaves its view on Idogen following the outcome of its rights issue. We also significantly lower our fair value range.

Redeye leaves its view on Idogen following the outcome of its rights issue. We also significantly lower our fair value range.
Börsvärldens nyhetsbrev
ANNONSER